Using special hydrogels to improve cell therapy for brain diseases
Programmable Hydrogels for Optimized Human Oligodendrocyte Transplantation in Demyelinating Disease
This study is looking at new ways to help transplant special brain cells to treat conditions like multiple sclerosis, using special gels to keep the cells safe during the process, which could lead to better recovery and improved brain function for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10868741 on NIH RePORTER |
What this research studies
This research focuses on enhancing the transplantation of human oligodendrocyte precursor cells (OPCs) to treat demyelinating diseases like multiple sclerosis. The team will develop innovative hydrogels that help protect these cells during injection, aiming to improve their survival and effectiveness in repairing damaged brain tissue. By addressing the challenges of cell death and immune response, this approach seeks to create a more favorable environment for successful cell therapy. Patients may benefit from improved neurological function and better outcomes in their treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with demyelinating diseases such as multiple sclerosis who are seeking advanced treatment options.
Not a fit: Patients with non-demyelinating neurological conditions or those who do not qualify for cell transplantation therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with demyelinating diseases, potentially restoring lost neurological functions.
How similar studies have performed: Previous research has shown promise in using cell therapies for neurological conditions, but this specific approach with hydrogels is relatively novel and untested.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Andreadis, Stelios Theoharis — State University of New York at Buffalo
- Study coordinator: Andreadis, Stelios Theoharis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.